FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:2767 December 23, 2004 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: Rofecoxib (Vioxx) was recently withdrawn from the market because of an increased risk of myocardial infarction and stroke. There is a similar public health concern about another coxib, valdecoxib (Bextra), which is used by 7 million patients worldwide.¹ To protect the safety of the public, we write to recommend that clinicians stop prescribing valdecoxib except in extraordinary circumstances. This recommendation is based on the long delay between the initial evidence of the cardiotoxicity of rofecoxib and its withdrawal, recent studies demonstrating the cardiotoxicity of valdecoxib in high-risk patients, the availability of other therapies not currently known to . . . [Full Text of this Article]

This article has been cited by other articles:

• Hoshino, T., Nakaya, T., Homan, T., Tanaka, K.-i., Sugimoto, Y., Araki, W., Narita, M., Narumiya, S., Suzuki, T., Mizushima, T. (2007). Involvement of Prostaglandin E2 in Production of Amyloid-beta Peptides Both in Vitro and in Vivo. J. Biol. Chem. 282: 32676-32688 [Abstract] [Full Text]  
• Clegg, D. O., Reda, D. J., Harris, C. L., Klein, M. A., O'Dell, J. R., Hooper, M. M., Bradley, J. D., Bingham, C. O. III, Weisman, M. H., Jackson, C. G., Lane, N. E., Cush, J. J., Moreland, L. W., Schumacher, H. R. Jr., Oddis, C. V., Wolfe, F., Molitor, J. A., Yocum, D. E., Schnitzer, T. J., Furst, D. E., Sawitzke, A. D., Shi, H., Brandt, K. D., Moskowitz, R. W., Williams, H. J. (2006). Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.. NEJM 354: 795-808 [Abstract] [Full Text]  
• Bolten, W W (2006). Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs. Ann Rheum Dis 65: 7-13 [Abstract] [Full Text]  
• Rodrigues, A. D. (2005). IMPACT OF CYP2C9 GENOTYPE ON PHARMACOKINETICS: ARE ALL CYCLOOXYGENASE INHIBITORS THE SAME?. Drug Metab. Dispos. 33: 1567-1575 [Abstract] [Full Text]  
• Tanaka, K.-i., Tomisato, W., Hoshino, T., Ishihara, T., Namba, T., Aburaya, M., Katsu, T., Suzuki, K., Tsutsumi, S., Mizushima, T. (2005). Involvement of Intracellular Ca2+ Levels in Nonsteroidal Anti-inflammatory Drug-induced Apoptosis. J. Biol. Chem. 280: 31059-31067 [Abstract] [Full Text]  
• Misak, A. (2005). Coxib medications to be handled with care. CMAJ 172: 330-330 [Full Text]  
• Topol, E. J. (2005). Arthritis Medicines and Cardiovascular Events--"House of Coxibs". JAMA 293: 366-368 [Full Text]  
• Gottlieb, S. (2005). Warnings issued over COX 2 inhibitors in US and UK. BMJ 330: 9-9 [Full Text]